论文部分内容阅读
目的观察外周血干细胞移植(PBSCT)治疗血液肿瘤临床疗效。方法自2001年3月~2007年4月,对283例血液肿瘤患者施行外周血干细胞移植,其中自体移植231例,异基因移植52例,观察其临床疗效和并发症。结果除1例ALL外,230例患者行自体外周血干细胞移植后造血功能均快速重建。异基因移植中急性移植物抗宿主病发生率23.1%,慢性移植物抗宿主病发生率21.2%,其中局限型占15.4%;9例患者于移植后1~16个月分别死于移植物抗宿主病、感染和疾病复发或进展,35例患者已无病存活3~46个月。结论外周血干细胞移植是治疗血液肿瘤的有效方法,依据患者疾病诊断、年龄、身体状况、供者情况选择移植方式。
Objective To observe the clinical efficacy of peripheral blood stem cell transplantation (PBSCT) in the treatment of hematological tumors. Methods From March 2001 to April 2007, peripheral blood stem cell transplantation was performed in 283 patients with hematological malignancies, including 231 autologous transplantation and allogeneic transplantation. The clinical efficacy and complications were observed. Results In addition to 1 case of ALL, 230 patients undergoing autologous peripheral blood stem cell transplantation are rapidly reconstructed hematopoietic function. The incidence of acute graft-versus-host disease in allogeneic transplantation was 23.1% and the incidence of chronic graft-versus-host disease was 21.2%, of which 15.4% was localized. Nine patients died of graft-versus-graft disease 1 to 16 months after transplantation Host disease, infection and disease recurrence or progression, 35 patients had disease-free survival of 3 to 46 months. Conclusion Peripheral blood stem cell transplantation is an effective method for the treatment of hematological neoplasm. According to the patient’s disease diagnosis, age, physical condition and donor status, the transplantation mode is selected.